Trial Data Revisit Carbapenem Alternatives for ESBL Bloodstream Infections
Results from the PETERPEN trial indicate piperacillin-tazobactam may perform similarly to meropenem for early treatment responses in certain ESBL bloodstream infection patients. However, carbapenems remain the recommended standard until final mortality findings are available and analyzed.
The PETERPEN trial examined whether piperacillin-tazobactam might be a viable alternative to meropenem in some cases of bloodstream infection caused by ESBL-producing organisms. Its early findings suggest similar responses during initial treatment for certain patients, but the evidence is not yet sufficient to change practice. Because mortality results are still pending, carbapenems continue to be the recommended standard for these infections. The story reflects ongoing clinical interest in comparing treatment options for ESBL bloodstream infections while awaiting definitive outcome data.
If confirmed, these findings could affect how clinicians discuss treatment choices for some ESBL bloodstream infections, potentially influencing antibiotic selection and stewardship discussions. Patients may benefit if alternatives prove safe and effective, but any change could carry risks until mortality data are clear. Hospitals, pharmacists, and infection-prevention teams may watch the final results closely, as guidance and local protocols could be revisited only after stronger evidence emerges.